IDH2 and astrocytoma (excluding glioblastoma): IDH mutant tumors molecularly evolve over time with IDH mutation being the initiating event with subsequent TP53 and ATRX alterations (astrocytomas) or 1p/19q codeletion (oligodendrogliomas) followed by TERT mutations (Bennett et al., 2025).